Maas Biolab Overview
Update this profile
Latest Deal Amount
Maas Biolab General Information Description
Operator of a biotechnology firm intended to develop a neuro-pharmaceutical drug. The company is developing a treatment for chronic neurodegenerative diseases including amyotrophic lateral sclerosis, alzheimer's, parkinson's and huntington's, enabling healthcare practitioners to access advanced drugs for better treatment.
Want to dig into this profile?
We’ll help you find what you need
Maas Biolab Signals
0.80%, 93rd %ile
219x, 100th %ile
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial
Maas Biolab Investors (4)
National institutes of Neurological Disorders and Stroke
Small Business Innovation Research and Small Business Technology Transfer Programs
U.S. Department of Health and Human Services
TEDCO Venture Capital
To view Maas Biolab’s complete investors history, request access »